Premium
Outcomes of oral lichen planus and oral lichenoid lesions treated with topical corticosteroid
Author(s) -
GonzalezMoles MA,
Bravo M,
GonzalezRuiz L,
Ramos P,
GilMontoya JA
Publication year - 2018
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12803
Subject(s) - medicine , triamcinolone acetonide , corticosteroid , clobetasol propionate , oral lichen planus , dermatology , adverse effect , gastroenterology , surgery
Objective To determine corticosteroid treatment effectiveness in patients with oral lichen planus/oral lichenoid lesions ( OLP / OLL ). Material and Methods Twenty‐one patients with OLP and eighty‐one patients with OLL received 0.05% clobetasol propionate ( CP ) or 0.05% triamcinolone acetonide ( TA ) in aqueous solution ( AS ) or orabase ( OB ), evaluating responses to treatment and follow‐up compliance. Results Lesions were atrophic (72 of 102; 70.6%), extensive (58 of 100; 58%), producing eating difficulties (62 of 102; 60.8%), and spontaneous pain (30 of 102; 29.4%); 50 patients (49%) received CP ‐ AS . The mean ± SD percentage of follow‐ups attended was 43 ± 32%. Symptom remission was achieved in 46% of patients receiving CP ‐ AS , 36.36% of those receiving TA ‐ AS , 20% of those receiving CP ‐ OB , and 25% of those receiving TA ‐ OB . Follow‐up compliance was poor in 66.7% of patients. Among 51 patients with continuous symptoms, 64.7% evidenced total remission at treatment completion; among 33 with intermittent symptoms, 73.1% had outbreaks 2–3 times/year and 51.5% controlled outbreaks with <6 corticosteroid applications. Adverse effects were observed in seven patients (6.8%) (moon face, hirsutism, capillary fragility) in induction stage, subsiding with dose; among 15 patients under maintenance treatment for >6 months, one showed hypothalamic–pituitary–adrenal ( HPA ) axis inhibition but not adrenal insufficiency. Conclusions Our treatment proved highly effective and safe. Recall programs are desirable to enhance follow‐up compliance.